Allopurinol, gout, and cardiovascular risk - Takeaways - MDSpire

Allopurinol, gout, and cardiovascular risk

  • By

  • Jalina Jannink

  • Arend Mosterd

  • Aernoud T L Fiolet

  • October 29, 2025

  • 0 min

Share

  • 1

    Patients with gout face increased cardiovascular risks, potentially due to hyperuricaemia and oxidative stress.

  • 2

    The ALL-HEART trial found no cardiovascular benefit from high-dose allopurinol in patients without gout.

  • 3

    A Dutch study showed that ischaemic cardiovascular events increased significantly during the first 30 days of allopurinol initiation.

  • 4

    Higher starting doses of allopurinol (>300 mg) were associated with greater cardiovascular risk compared to lower doses.

  • 5

    Concomitant use of colchicine mitigated early cardiovascular risks associated with allopurinol treatment.

Original Source(s)

Allopurinol, gout, and cardiovascular risk

  • by Jalina Jannink, Arend Mosterd, Aernoud T L Fiolet

  • October 29, 2025

Related Content

Do Urate Targets Influence CV Risk?

Researchers examine whether achieving treat-to-target serum urate levels with urate-lowering treatment affects long-term cardiovascular outcomes in patients with gout.

Link Between Serum Uric Acid to HDL Cholesterol Ratio and Overall as Well as Cardiovascular Mortality in Gout Patients

AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models